Regenerative medicines company AVITA Medical (AVH:ASX) has reported a 46 per cent increase in revenue to $49.8 million for 2023. …
Investors back AVITA Medical after it reported full-year results
February 26, 2024 Australian Biotech
Latest Video
New Stories
-
AstraZeneca confirms pricing the issue, and acts to create a patient access program
June 16, 2026 - - Latest News -
When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution
June 16, 2026 - - Latest News -
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News